Migraine is a fairly common disease that is a leading cause of disability worldwide. 15% of
the general population suffer from migraine headaches. Although there are currently many
options for the treatment of acute migraine, these treatment options, such as acetaminophen,
nonsteroidal anti-inflammatory drugs (NSAIDS), triptans, combinations analgesics and
antiemetics, have insufficient efficacy and significant side effects. Therefore, there is a
need for new treatment modalities in migraine. Sphenopalatine ganglion (SPG) block is gaining
interest as an effective treatment for migraine, other headaches and facial pain syndromes.
In our study, we aimed to block the Sphenopalatine ganglion with a local anesthetic drug and
compare it with the placebo control group.